Day 2 - Evening

Group 6A: Metastatic Breast Cancer; Exceptional Responders; Predictive Biomarkers Sold Out

Group 6B: HER2-negative & BRCA+ Breast Cancer; Latin American Populations; Genetic Testing

Group 6C: HER2-low Breast Cancer; Sequencing Antibody-drug Conjugates Last Few Tickets

Group 6D: HR+ Breast Cancer; Treatment Resistance Last Few Tickets

Group 6E: HR+, HER2-low, & HER2-0 Breast Cancer